Benefits of using DIDB® and e-PKGene® applications

From preclinical

  • Provide context for the interpretation of results obtained for candidate compounds
  • Support static predictions and PBPK models
  • Help optimize preclinical study design
    • Cell system, incubation conditions, tests concentrations, choice of substrate/inhibitor, etc.
  • Allow assessment of measurement variability
    • Inter-lab, substrate system-dependency, etc.

To clinical

  • Assists with design of clinical trials
    • Guide choice of appropriate index drugs and study design
    • Refine inclusion/exclusion criteria
    • Help select dose, duration, timing of administration of object and precipitant drugs
    • Provide PK variability data for power calculation
    • Identify known substrates of enzymes/transporters among marketed drugs to understand drug-drug interaction (DDI) and gene-drug interaction (GDI) risk
  • Provide in vitro evidence to explain clinical results
    • Improve understanding of drug interactions mechanisms
  • Help users gain insight on DDI risk and possible clinical outcomes
  • Support drug labeling recommendations and the safe use of medications in various patient populations
  • Access regulatory DDI and GDI studies for recently marketed drugs
  • Provide reference resource for assessment of drug interaction safety
  • Guide healthcare providers in their clinical decision
  • Ultimately help implement personalized prescriptions
    • Help select the most appropriate drug and dose for each patient